A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung...

Area of Science:

• Oncology
• Radiology
• Pharmacology

Background:

• Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a distinct subtype.
• Understanding radiological and clinical features is crucial for treatment strategies.
• Crizotinib is a targeted therapy for ALK-positive NSCLC.

Purpose of the Study:

• To evaluate radiological and clinical features in metastatic ALK+ NSCLC patients.
• To assess crizotinib efficacy in different treatment lines.
• To identify novel associations between patient characteristics and metastatic patterns.

Main Methods:

• National, non-interventional, multicenter, retrospective archive screening study.
• Inclusion of 367 patients treated between 2013-2017.
• Analysis of demographic, clinical, radiological imaging, and treatment data.

Main Results:

• Median age at diagnosis was 54 years; 45.4% were smokers.
• Peripheral tumors (55.9%), cavitary lesions (7.7%), and pleural effusion (42.9%) were noted.
• Objective response rate to crizotinib was 61.9%; median progression-free survival was 14 months.
• Adrenal metastasis higher in males/smokers; pleural effusion higher in non-smokers (novel finding).
• Highest response rates observed with crizotinib as second-line treatment.

Conclusions:

• Radiological and clinical features are largely consistent with literature, with some population-specific differences.
• Crizotinib demonstrates significant efficacy in metastatic ALK+ NSCLC.
• Novel associations found regarding metastasis patterns in relation to smoking status and sex.